Miami Study Boosts Alzheimer’s Decline Prediction by 22.8% With Blood Tests and Cognitive Screening
Updated
Updated · University of Miami · Jul 7
Miami Study Boosts Alzheimer’s Decline Prediction by 22.8% With Blood Tests and Cognitive Screening
3 articles · Updated · University of Miami · Jul 7
Summary
159 adults with cognitive impairment but no dementia were tracked for about 41.5 months, and researchers found blood biomarkers plus specialized cognitive testing predicted functional decline better than biomarkers alone.
The combined model added up to 22.8% more explained variance in decline rates, addressing a key gap in Alzheimer’s care: biological signs can appear years before symptoms and do not reliably show who will worsen.
Plasma p-tau217 was strongly tied to baseline functional status, while neurofilament light chain predicted the pace of decline even after adjustments for demographics, genetics and amyloid PET status.
LASSI-L cognitive challenge results—especially poorer recall and more intrusion errors—independently signaled faster worsening, suggesting the tests capture real-world effects that blood measures miss.
The University of Miami team said the approach could sharpen early diagnosis, monitoring and clinical trial enrollment in pre-dementia patients, with next research focused on how common chronic conditions affect biomarker accuracy.
If a blood test could reveal your future cognitive decline, what are the hidden psychological risks of knowing this information?
A new test predicts Alzheimer's decline, but who can actually access and afford the full diagnostic process it requires?
Combining Blood Biomarkers and Cognitive Challenge Tests Improves Alzheimer’s Functional Decline Prediction by 22.8%: Insights from the Miami Study and the Future of Early Detection
Overview
A recent study from the University of Miami Miller School of Medicine, published in the Journal of Alzheimer’s Disease, marks a major step forward in predicting how quickly older adults at risk for Alzheimer’s may lose daily functioning. By combining blood-based biomarkers with cognitive challenge tests, the researchers created a more accurate way to track disease progression. This dual approach explained up to 22.8% more of the changes in functional decline than using biomarkers alone, showing that both biological and cognitive assessments are important for better prediction and early intervention in Alzheimer’s disease.